Masitinib in neurodegenerative disease

OVERVIEW 

AB Science is developing masitinib in multiple sclerosis and Alzheimer's disease and Amyotrophic Lateral Sclerosis


Pathology Study Current status
Progressive forms of multiple sclerosis
  • Indication : treatment of patients with primary progressive or relapse-free secondary progressive multiple sclerosis
  • Objective : to compare efficacy and safety of masitinib versus placebo
  • Design : 96-week, prospective, multicenter, randomised, double-blind, placebo-controlled, 2-parallel group
Phase 3
Recruitment completed
Alzheimer's disease
  • Indication : treatment of patients with mild to moderate Alzheimer's disease
  • Objective : to evaluate efficacy and safety of masitinib combination with cholinesterase inhibitors and/or memantine to placebo in combination with cholinesterase inhibitors and/or memantine
  • Design : 24-week, prospective, multicenter, randomized, double-blind, placebo-controlled, 3-parallel group
Phase 3
On-going
Amyotrophic Lateral Sclerosis
  • Indication : Treatment of patients suffering from Amyotrophic Lateral Sclerosis
  • Objective : compare the efficacy and safety of masitinib combined with riluzole versus placebo combined with riluzole
  • Design : 48-week with possible extension, multicenter, randomised, double-blind, placebo-controlled, parallel group
Phase 3
Study completed